Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does lipitor's mechanism reduce muscle damage?How does one's income affect vascepa assistance?How are aurobindo tablets manufactured to ensure accurate clonazepam doses?Can advil be combined with other offers?When will lipitor's effects resume?
See the DrugPatentWatch profile for cosentyx
Why might Cosentyx lose effectiveness over time? Cosentyx (secukinumab) is an interleukin-17 inhibitor approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Some patients experience loss of response after years of treatment. Primary non-response occurs in 20-30% of patients, while secondary loss of response reaches 20-40% by year five in registry data. Secondary loss arises mainly from anti-drug antibodies that bind secukinumab and reduce its target engagement.
Other Questions About Cosentyx :